Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...
Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...
Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...
Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. Healthcare lease accounting insights: How two organizations ...
World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven ...
Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that the subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), knowingly submitted or caused false ...
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Pfizer has agreed to pay $59.75 million to settle claims that Biohaven Pharmaceutical Holding Co., which it acquired in 2022, defrauded Medicare and other healthcare programs by paying kickbacks ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...